The text starts here.

News Release

July 4, 1996

Eisai Starts Construction of 4th Production (Packaging) Facility at Kawashima Production Facilities

July 4, 1996 -- Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced today the start of construction of the 4th production facility for packaging for tablets, capsules and granules and other solid type formulations at Kawashima production facilities.

Eisai will build a packaging facility which has a total floor area of 18,593 square meters on 12,357 square meters of land at Kawashima production facilities in Gifu prefecture. The plant is scheduled to be operational in February 1998. Eisai plans to invest about 65 million Yen in the project.

Eisai built its first packaging facility for solid type formulation at Kawashima production facilities in 1969, and has expanded packaging functions to meet the production quantities

Eisai has decided to construct the 4th production facility which can respond to the future expansion of distribution and a variety of packaging and formulation needs. Eisai also aims to build quality into the production system corresponding to the revised GMP (Good Manufacturing Practice) code with the automation of production.

At the facility, Eisai plans to manufacture ethical pharmaceuticals including SELBEX(TM), a gastritis/gastric ulcer medication, GLAKAY(TM), a vitamin K2 treatment for osteoporosis and INFREE(TM), an analgesic/anti-inflammatory agent.

Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of over $2.5 billion in fiscal year 1995 with approximately 14 percent of sales spent for research and development.